Paula Cramer

Kerpener Str. 62
Koeln, NW 50937, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Vulvar and Pelvic Origin Lower Extremity Varicose Veins: A Survey of Current Evaluation and Management.

Vulvar and Pelvic Origin Lower Extremity Varicose Veins: A Survey of Current Evaluation and Management.

Journal: Journal of vascular surgery. Venous and lymphatic disorders

Published: June 24, 2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: May 06, 2026

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma

Published: March 17, 2026

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Journal: European journal of haematology

Published: December 12, 2025

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 07, 2025

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 27, 2024

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Journal: Blood

Published: September 17, 2024

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 30, 2024

Immunoadsorption is equally effective as plasma exchange in paediatric neuroimmunological disorders - A retrospective multicentre study.

Immunoadsorption is equally effective as plasma exchange in paediatric neuroimmunological disorders - A retrospective multicentre study.

Journal: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society

Published: July 16, 2024

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.

Journal: American journal of hematology

Published: January 07, 2024

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.

Journal: American journal of hematology

Published: December 01, 2023

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.

Journal: Blood

Published: September 28, 2023

Showing 1-12 of 72

Last Updated: 09/26/2026